

Title (en)  
IMIDAZO [1,2-A] PYRIMIDINE DERIVATIVES, PROCESS FOR THEIR PREPARATION, USE AS MEDICAMENTS, PHARMACEUTICAL COMPOSITIONS AND USE AS MET INHIBITORS

Title (de)  
IMIDAZO[1,2-A]PYRIMIDINDERIVATE, VERFAHREN ZU DEREN HERSTELLUNG, VERWENDUNG ALS MEDIKAMENTE, PHARMAZEUTISCHE ZUSAMMENSETZUNGEN UND VERWENDUNG ALS MET-INHIBITOREN

Title (fr)  
DERIVES IMIDAZO [1,2-A] PYRIMIDINE, LEUR PROCEDE DE PREPARATION, LEUR APPLICATION A TITRE DE MEDICAMENTS, COMPOSITIONS PHARMACEUTIQUES ET UTILISATION COMME INHIBITEURS DE MET

Publication  
**EP 2318414 A2 20110511 (FR)**

Application  
**EP 09737062 A 20090716**

Priority  
• FR 2009051408 W 20090716  
• FR 0804086 A 20080718

Abstract (en)  
[origin: WO2010007318A2] The invention relates to the novel products of formula (I): in which: n = 0, 1 or 2; X is H, Hal or alk; R is H, NH<sub>2</sub>, NHalk or N(alk)<sub>2</sub>; Ra is H, Hal, -O-cycloalkyl, -O-alkyl, -O-aryl, -O-heteroaryl, -NRd(cycloalkyl), -NRd(alkyl), -NRd(aryl), -NRd(heteroaryl), alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl, all optionally substituted; Rb is H, Rc, -COORc-CO-Rc or -CO-NRcRd; where Rc is alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl, all optionally substituted; Rd is H, alk or cycloalkyl; these products being in all the isomer forms and the salts, as medicaments, in particular as MET inhibitors.

IPC 8 full level  
**C07D 487/04** (2006.01); **A61K 31/519** (2006.01); **A61K 31/5377** (2006.01); **A61P 35/00** (2006.01); **C07D 277/82** (2006.01)

CPC (source: EP KR US)  
**A61K 31/519** (2013.01 - KR); **A61P 3/00** (2017.12 - EP); **A61P 3/10** (2017.12 - EP); **A61P 7/02** (2017.12 - EP); **A61P 7/04** (2017.12 - EP); **A61P 9/00** (2017.12 - EP); **A61P 9/10** (2017.12 - EP); **A61P 11/06** (2017.12 - EP); **A61P 17/06** (2017.12 - EP); **A61P 19/02** (2017.12 - EP); **A61P 21/00** (2017.12 - EP); **A61P 25/00** (2017.12 - EP); **A61P 27/00** (2017.12 - EP); **A61P 27/02** (2017.12 - EP); **A61P 29/00** (2017.12 - EP); **A61P 35/00** (2017.12 - EP); **A61P 37/00** (2017.12 - EP); **A61P 37/08** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 277/82** (2013.01 - EP US); **C07D 417/12** (2013.01 - KR); **C07D 487/04** (2013.01 - EP KR US)

Citation (search report)  
See references of WO 2010007318A2

Designated contracting state (EPC)  
AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

Designated extension state (EPC)  
AL BA RS

DOCDB simple family (publication)  
**WO 2010007318 A2 20100121**; **WO 2010007318 A3 20100408**; AR 072820 A1 20100922; AU 2009272518 A1 20100121; BR PI0915920 A2 20180710; CA 2730964 A1 20100121; CL 2011000118 A1 20110715; CN 102159577 A 20110817; CO 6341634 A2 20111121; CR 20110031 A 20110314; DO P2011000019 A 20110215; EA 201170224 A1 20110830; EC SP11010765 A 20110228; EP 2318414 A2 20110511; FR 2933982 A1 20100122; IL 210708 A0 20110331; JP 2011528339 A 20111117; KR 20110043680 A 20110427; MA 32564 B1 20110801; MX 2011000670 A 20110411; NI 201100020 A 20110721; PE 20110584 A1 20110910; SV 2011003811 A 20110429; TW 201011025 A 20100316; US 2011263593 A1 20111027; UY 31998 A 20100226; ZA 201100428 B 20120328

DOCDB simple family (application)  
**FR 2009051408 W 20090716**; AR P090102728 A 20090717; AU 2009272518 A 20090716; BR PI0915920 A 20090716; CA 2730964 A 20090716; CL 2011000118 A 20110118; CN 200980136540 A 20090716; CO 11004605 A 20110118; CR 20110031 A 20110117; DO 2011000019 A 20110117; EA 201170224 A 20090716; EC SP11010765 A 20110118; EP 09737062 A 20090716; FR 0804086 A 20080718; IL 21070811 A 20110117; JP 2011517980 A 20090716; KR 20117003698 A 20090716; MA 33618 A 20110215; MX 2011000670 A 20090716; NI 201100020 A 20110117; PE 2011000049 A 20090716; SV 2011003811 A 20110117; TW 98124145 A 20090716; US 201113007830 A 20110117; UY 31998 A 20090717; ZA 201100428 A 20110117